EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

ADAPT NXT : Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Ali A Habib, Kristl G Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés-Vicente iD, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H Jimenez, Daniela Hristova und 5 weitere

Annals of Clinical and Translational Neurology · 2025-06 · 12 (6) · 1162-1170

DOI: 10.1002/acn3.70051 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 14.04.2025. Verfasst von Ali A Habib und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California, Irvine, Orange, California, USA. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: argenx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.

Methods

Adult participants with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis (gMG) were randomized 3:1 to Q2W or fixed cycles dosing of efgartigimod (10 mg/kg intravenously) for 21 weeks. The primary endpoint was the mean change from baseline in total Myasthenia Gravis Activities of Daily Living (MG‐ADL) score averaged across 21 weeks.

Results

Sixty‐nine participants were treated (fixed cycles, n = 17; Q2W, n = 52). Least squares (LS) mean (95% CI) of the change from baseline in MG‐ADL total score from Weeks 1 to 21 was −5.1 (−6.5 to −3.8) in the fixed cycles arm and −4.6 (−5.4 to −3.8) in the Q2W arm. Clinical improvements were observed in MG‐ADL total scores as early as Week 1 and were maintained throughout the study. Achievement of minimal symptom expression (MG‐ADL: 0–1) from Weeks 1 to 21 occurred in 47.1% ( n = 8/17) and 44.2% ( n = 23/52) of participants in the fixed cycles and Q2W arms, respectively. Efgartigimod was well tolerated; COVID‐19, headache, and upper respiratory tract infection were the most common treatment‐emergent adverse events.

Interpretation

Efgartigimod administered as either fixed cycles or Q2W dosing results in rapid, robust, and sustained clinically meaningful improvement. These results build upon previous studies and provide additional efgartigimod dosing approaches to achieve and sustain clinical efficacy in patients with gMG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHumansMaleFemaleMiddle AgedAdultAgedActivities of Daily LivingDrug Administration ScheduleTreatment Outcome

Stichwörter der Autor:innen

efgartigimodgeneralized myasthenia gravismyasthenia gravis activities of daily livingneonatal Fc receptor

Autor:innen und Institutionen

  • Department of Neurology, University of California, Irvine, Orange, California, USA.
  • Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory for Muscle Diseases and Neuropathies, KU Leuven, Leuven, Belgium.
  • Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, Toronto, Ontario, Canada.
  • University of Toronto, Toronto, Ontario, Canada.
  • Austin Neuromuscular Center, Austin, Texas, USA.

ORCID-Profile: Elena Cortés-Vicente, Shahram Attarian

Förderung

  • argenx

Zitieren

APA

Habib, A. A., Claeys, K. G., Bril, V., Hussain, Y., Gwathmey, K., Sahagian, G., Cortés-Vicente, E., Brauer, E., Gelinas, D., Sumbul, A., Jimenez, R. H., Hristova, D., Masschaele, D., Mantegazza, R., Meisel, A., Attarian, S., & ADAPT NXT Study Group (2025). ADAPT NXT : Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis. Annals of Clinical and Translational Neurology, 12(6), 1162-1170. https://doi.org/10.1002/acn3.70051

Vancouver

Habib AA, Claeys KG, Bril V, Hussain Y, Gwathmey K, Sahagian G, et al. ADAPT NXT : Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis. Annals of Clinical and Translational Neurology. 2025;12(6):1162-1170. doi:10.1002/acn3.70051

BibTeX
@article{Habib2025,
  author = {Habib, Ali A and Claeys, Kristl G and Bril, Vera and Hussain, Yessar and Gwathmey, Kelly and Sahagian, Gregory and Cortés-Vicente, Elena and Brauer, Edward and Gelinas, Deborah and Sumbul, Anne and Jimenez, Rosa H and Hristova, Daniela and Masschaele, Delphine and Mantegazza, Renato and Meisel, Andreas and Attarian, Shahram and ADAPT NXT Study Group, ADAPT NXT Study Group},
  title = {ADAPT NXT : Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {6},
  pages = {1162--1170},
  doi = {10.1002/acn3.70051}
}
Kostenlos starten →